Trial · NCT07893119
Effect of Voiding Position (Standing in the Shower vs. Sitting) on Post- Void Residual Urine Volume (PVR) After Removal of Urinary Catheter in Women Following Vaginal Delivery With Epidural Analgesia: A Double- Blind Randomized Controlled Trial
NCT07893119, Not applicable, Not yet recruiting, Assuta Ashdod Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Voiding Position (Standing in the Shower vs. Sitting) on Post- Void Residual Urine Volume (PVR) After Removal of Urinary Catheter in Women Following Vaginal Delivery With Epidural Analgesia: A Double- Blind Randomized Controlled Trial. Trials, record NCT07893119. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07893119
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Effect of Voiding Position (Standing in the Shower vs. Sitting) on Post- Void Residual Urine Volume (PVR) After Removal of Urinary Catheter in Women Following Vaginal Delivery With Epidural Analgesia: A Double- Blind Randomized Controlled Trial
- NCT number
- NCT07893119
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Assuta Ashdod Hospital
- Conditions
- Postpartum Urinary Retention
- Interventions
- Standing in the shower, Sitting on the toilet
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with Post-Void Residual Volume (PVR) > 150 mL | Immediately after the first void (within a maximum of 6 hours following catheter removal) | Post-void residual urine volume (PVR) greater than 150 mL, measured by bladder ultrasound (bladder scan) immediately after the first spontaneous void following catheter removal. This cut-off is consistent with definitions of covert postpartum urinary retention. |
| Secondary | Mean Post-Void Residual Volume (PVR) | Immediately after the first void (within a maximum of 6 hours following catheter removal) | Mean PVR measured in milliliters (mL) as a continuous variable. |
| Secondary | Incidence of Overt Postpartum Urinary Retention (PUR) | Up to 6 hours after catheter removal | Inability to void within 6 hours after catheter removal. |
| Secondary | Need for Recatheterization | Within 24-48 hours postpartum | he need for recatheterization (yes/no) and the number of recatheterizations required, evaluating the success rate of the voiding trial. |
| Secondary | Time to First Void | Up to 6 hours after catheter removal | Time elapsed from catheter removal to the first spontaneous void, measured in minutes. |
| Secondary | Incidence of Urinary Tract Infection (UTI) | Within 7 days postpartum | Development of a urinary tract infection confirmed by clinical signs/symptoms and/or laboratory tests. |
| Secondary | Readmission or Emergency Department Presentation Due to Urinary Retention | Within 7 days postpartum | Rate of presentation to the emergency department or readmission specifically due to urinary retention. |
| Secondary | Patient-Reported Pain During Micturition and Perineal Pain | During the first void after catheter removal (within a maximum of 6 hours) | Pain levels assessed using a numeric rating scale ranging from 0 (no pain) to 10 (worst possible pain), focusing on pain during micturition and general perineal pain. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07893119
GET https://conductscience.org/api/trials/v1/NCT07893119/registered